Breast cancer stem cells: Responsible for therapeutic resistance and relapse?

Hasan Korkaya, Fayaz Malik

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Since the war on cancer was waged more than 30 years ago, the fact remains that the metastatic breast cancer is still incurable and patients will ultimately die from this disease [1]. American Cancer Society has estimated that in the year 2012, there will be about 229,060 new cases of breast cancer and an estimated 39,920 new deaths caused by breast cancer in the United States alone [2]. Majority of breast cancer-related deaths are primarily due to metastatic disease which display poor prognosis with an estimated 5-year survival of ~20 %. Furthermore, therapeutic resistance and relapse are strongly associated with metastatic disease in breast cancer patients [1]. Despite the fact that the heterogeneity of tumor cells had been widely acknowledged, it has not been validated until the 1990s due to lack of markers and techniques. D. Bonnet and J. Dick were the first to describe the hierarchical organization of acute myeloid leukemia (AML) and the existence of cancer stem cells (CSC). This was quickly followed by the identification of CSCs from number of malignancies enabling us to better characterize these cells in mouse models and preclinical settings. These ongoing functional studies suggested that CSCs may explain the failure to treat advance metastatic tumors. Thus the seed and soil hypothesis proposed by Stephen Paget more than 120 years ago may re-framed in a modern context explaining the ability of subset of tumor cells seed or CSCs to disseminate and metastasize to secondary organs where nutrient-rich microenvironment soil stimulates the secondary tumor growth by enhancing CSC self-renewal.

Original languageEnglish (US)
Title of host publicationBreast Cancer Metastasis and Drug Resistance
Subtitle of host publicationProgress and Prospects
PublisherSpringer New York
Pages385-398
Number of pages14
Volume9781461456476
ISBN (Electronic)9781461456476
ISBN (Print)1461456460, 9781461456469
DOIs
StatePublished - Aug 1 2013

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Recurrence
Neoplasms
Seeds
Soil
Therapeutics
Acute Myeloid Leukemia
Food
Survival
Growth

Keywords

  • Aldehyde dehydrogenase (ALDH)
  • Biomarkers
  • Breast cancer stem cell self-renewal
  • Cancer stem cell (CSC) targeted therapies
  • Cancer stem cells (CSCs)
  • Cyclopamine
  • Cytokines
  • Metastasis
  • Relapse
  • Therapeutic resistance
  • Trastuzumab resistance
  • Xenografts

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Korkaya, H., & Malik, F. (2013). Breast cancer stem cells: Responsible for therapeutic resistance and relapse? In Breast Cancer Metastasis and Drug Resistance: Progress and Prospects (Vol. 9781461456476, pp. 385-398). Springer New York. https://doi.org/10.1007/978-1-4614-5647-6_21

Breast cancer stem cells : Responsible for therapeutic resistance and relapse? / Korkaya, Hasan; Malik, Fayaz.

Breast Cancer Metastasis and Drug Resistance: Progress and Prospects. Vol. 9781461456476 Springer New York, 2013. p. 385-398.

Research output: Chapter in Book/Report/Conference proceedingChapter

Korkaya, H & Malik, F 2013, Breast cancer stem cells: Responsible for therapeutic resistance and relapse? in Breast Cancer Metastasis and Drug Resistance: Progress and Prospects. vol. 9781461456476, Springer New York, pp. 385-398. https://doi.org/10.1007/978-1-4614-5647-6_21
Korkaya H, Malik F. Breast cancer stem cells: Responsible for therapeutic resistance and relapse? In Breast Cancer Metastasis and Drug Resistance: Progress and Prospects. Vol. 9781461456476. Springer New York. 2013. p. 385-398 https://doi.org/10.1007/978-1-4614-5647-6_21
Korkaya, Hasan ; Malik, Fayaz. / Breast cancer stem cells : Responsible for therapeutic resistance and relapse?. Breast Cancer Metastasis and Drug Resistance: Progress and Prospects. Vol. 9781461456476 Springer New York, 2013. pp. 385-398
@inbook{59128806e7894ffda2134fa784808108,
title = "Breast cancer stem cells: Responsible for therapeutic resistance and relapse?",
abstract = "Since the war on cancer was waged more than 30 years ago, the fact remains that the metastatic breast cancer is still incurable and patients will ultimately die from this disease [1]. American Cancer Society has estimated that in the year 2012, there will be about 229,060 new cases of breast cancer and an estimated 39,920 new deaths caused by breast cancer in the United States alone [2]. Majority of breast cancer-related deaths are primarily due to metastatic disease which display poor prognosis with an estimated 5-year survival of ~20 {\%}. Furthermore, therapeutic resistance and relapse are strongly associated with metastatic disease in breast cancer patients [1]. Despite the fact that the heterogeneity of tumor cells had been widely acknowledged, it has not been validated until the 1990s due to lack of markers and techniques. D. Bonnet and J. Dick were the first to describe the hierarchical organization of acute myeloid leukemia (AML) and the existence of cancer stem cells (CSC). This was quickly followed by the identification of CSCs from number of malignancies enabling us to better characterize these cells in mouse models and preclinical settings. These ongoing functional studies suggested that CSCs may explain the failure to treat advance metastatic tumors. Thus the seed and soil hypothesis proposed by Stephen Paget more than 120 years ago may re-framed in a modern context explaining the ability of subset of tumor cells seed or CSCs to disseminate and metastasize to secondary organs where nutrient-rich microenvironment soil stimulates the secondary tumor growth by enhancing CSC self-renewal.",
keywords = "Aldehyde dehydrogenase (ALDH), Biomarkers, Breast cancer stem cell self-renewal, Cancer stem cell (CSC) targeted therapies, Cancer stem cells (CSCs), Cyclopamine, Cytokines, Metastasis, Relapse, Therapeutic resistance, Trastuzumab resistance, Xenografts",
author = "Hasan Korkaya and Fayaz Malik",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/978-1-4614-5647-6_21",
language = "English (US)",
isbn = "1461456460",
volume = "9781461456476",
pages = "385--398",
booktitle = "Breast Cancer Metastasis and Drug Resistance",
publisher = "Springer New York",

}

TY - CHAP

T1 - Breast cancer stem cells

T2 - Responsible for therapeutic resistance and relapse?

AU - Korkaya, Hasan

AU - Malik, Fayaz

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Since the war on cancer was waged more than 30 years ago, the fact remains that the metastatic breast cancer is still incurable and patients will ultimately die from this disease [1]. American Cancer Society has estimated that in the year 2012, there will be about 229,060 new cases of breast cancer and an estimated 39,920 new deaths caused by breast cancer in the United States alone [2]. Majority of breast cancer-related deaths are primarily due to metastatic disease which display poor prognosis with an estimated 5-year survival of ~20 %. Furthermore, therapeutic resistance and relapse are strongly associated with metastatic disease in breast cancer patients [1]. Despite the fact that the heterogeneity of tumor cells had been widely acknowledged, it has not been validated until the 1990s due to lack of markers and techniques. D. Bonnet and J. Dick were the first to describe the hierarchical organization of acute myeloid leukemia (AML) and the existence of cancer stem cells (CSC). This was quickly followed by the identification of CSCs from number of malignancies enabling us to better characterize these cells in mouse models and preclinical settings. These ongoing functional studies suggested that CSCs may explain the failure to treat advance metastatic tumors. Thus the seed and soil hypothesis proposed by Stephen Paget more than 120 years ago may re-framed in a modern context explaining the ability of subset of tumor cells seed or CSCs to disseminate and metastasize to secondary organs where nutrient-rich microenvironment soil stimulates the secondary tumor growth by enhancing CSC self-renewal.

AB - Since the war on cancer was waged more than 30 years ago, the fact remains that the metastatic breast cancer is still incurable and patients will ultimately die from this disease [1]. American Cancer Society has estimated that in the year 2012, there will be about 229,060 new cases of breast cancer and an estimated 39,920 new deaths caused by breast cancer in the United States alone [2]. Majority of breast cancer-related deaths are primarily due to metastatic disease which display poor prognosis with an estimated 5-year survival of ~20 %. Furthermore, therapeutic resistance and relapse are strongly associated with metastatic disease in breast cancer patients [1]. Despite the fact that the heterogeneity of tumor cells had been widely acknowledged, it has not been validated until the 1990s due to lack of markers and techniques. D. Bonnet and J. Dick were the first to describe the hierarchical organization of acute myeloid leukemia (AML) and the existence of cancer stem cells (CSC). This was quickly followed by the identification of CSCs from number of malignancies enabling us to better characterize these cells in mouse models and preclinical settings. These ongoing functional studies suggested that CSCs may explain the failure to treat advance metastatic tumors. Thus the seed and soil hypothesis proposed by Stephen Paget more than 120 years ago may re-framed in a modern context explaining the ability of subset of tumor cells seed or CSCs to disseminate and metastasize to secondary organs where nutrient-rich microenvironment soil stimulates the secondary tumor growth by enhancing CSC self-renewal.

KW - Aldehyde dehydrogenase (ALDH)

KW - Biomarkers

KW - Breast cancer stem cell self-renewal

KW - Cancer stem cell (CSC) targeted therapies

KW - Cancer stem cells (CSCs)

KW - Cyclopamine

KW - Cytokines

KW - Metastasis

KW - Relapse

KW - Therapeutic resistance

KW - Trastuzumab resistance

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=84949180230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949180230&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-5647-6_21

DO - 10.1007/978-1-4614-5647-6_21

M3 - Chapter

AN - SCOPUS:84949180230

SN - 1461456460

SN - 9781461456469

VL - 9781461456476

SP - 385

EP - 398

BT - Breast Cancer Metastasis and Drug Resistance

PB - Springer New York

ER -